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ABSTRACT
OBJECTIVE: To describe mortality due to hepatitis B and C as underlying cause in the 
municipality of São Paulo, verifying the trend of these rates, and to assess the association of 
these diseases with others, from 2002 to 2016.
METHODS: This is a time series study on mortality due to hepatitis B and C according to sex, 
with data from the Sistema de Informação de Mortalidade (SIM – Mortality Information Sistem). 
Prais Winsten regression was used in rate trend analysis.
RESULTS: The findings of this study showed a trend of decline of mortality from hepatitis B 
and C in recent years, particularly among males. These infections were important associated 
causes of liver cell carcinoma and HIV. The proportion of deaths under 70 years of age stands out.
CONCLUSIONS: The study provides a baseline for research on mortality trend and the impact 
of interventions, given the history of expanded detection and supply of treatments, including 
the most recent antivirals in Brazil, since 2015.
DESCRIPTORS: Hepatitis B. Hepatitis C. Mortality, trends. Time Series Studies. Correspondence: 
Ana Paula Sayuri Sato 
Av. Dr. Arnaldo, 715  
01246-904 São Paulo, SP, Brazil 
E-mail: sah@usp.br
Received: Nov 28, 2019
Approved: Mar 18, 2020
How to cite: Sato APS, Koizumi IK, 
Farias NSO, Silva CRC, Cardoso 
MRA, Figueiredo GM.  Mortality 
trend due to hepatitis B and C in 
the city of São Paulo, 2002–2016. 
Rev Saude Publica. 2020;54:124.
Copyright: This is an open-access 
article distributed under the 
terms of the Creative Commons 
Attribution License, which permits 
unrestricted use, distribution, and 
reproduction in any medium, 
provided that the original author 
and source are credited.
http://www.rsp.fsp.usp.br/
2
Hepatitis B and C mortality in São Paulo Sato APS et al.
https://doi.org/10.11606/s1518-8787.2020054002231
INTRODUCTION
Hepatitis B and C have great magnitude in the world, with estimates of about 257 million 
people chronically infected by the first (HBV) and 71 million by the second (HCV)1. In Brazil, 
a population survey performed in the Brazilian capitals and the Federal District in the 
2010s showed prevalence of 0.37% and 7.40% for the surface antigen of virus B (HBsAg) 
and against its nucleus (Anti-HBc), respectively, and 1.38 for the antibody against virus 
C (Anti-HCV)2–4. This resulted in an estimate for the population inhabiting these areas of 
430,658 of people with Anti-HCV reactivity, being 36.70% viremic4. In 2016, the Brazilian 
Ministry of Health estimated a prevalence of 0.70% nationwide and of 657,000 people with 
the active hepatitis C virus, aiming to establish a baseline to estimate the cases to be 
diagnosed and treated annually, in order to meet targets and eliminate viral hepatitis by 
20305. In a more recent publication, these estimates were updated to 0.53% and 632,000, 
respectively6. This information shows the importance of these infections in Brazil and the 
challenge for health services in detecting and treating patients.
Chronic HBV or HCV has been associated with an increased risk of death, especially from 
causes related to the development of liver diseases, such as cirrhosis or hepatocellular 
carcinoma (HCC). In 2015, 887,000 people died as a result of HBV infection7, and, 
in 2016, approximately 399,000 die each year with hepatitis C, mainly from cirrhosis and 
hepatocellular carcinoma8.
Viral hepatitis is among the main causes of death worldwide, being HCC the only cancer 
that substantially increased between 1990 and 20139. In Brazil, the mortality rate from 
hepatitis B from 2000 to 2009 was 0.3/100,000 inhabitants-year10.
It should be noted that studies on hepatitis C mortality are scarce5. In the municipality of 
São Paulo, the mortality trend due to hepatitis B or C has not yet been evaluated. Thus, the 
objective of this study was to describe mortality due to hepatitis B and C as underlying cause 
in the city of São Paulo, verifying the trend of these rates, and to evaluate the participation 
of these infections as causes associated with others from 2002 to 2016.
METHODS
This is an ecological time series on mortality from viral hepatitis B and C, from 2002 to 
2016, including deaths of residents in the city of São Paulo.
The São Paulo capital has a territorial area of 1,522,986 km2, an estimated population of 
11,638,802 inhabitants11 in 2016, and Municipal Human Development Index of 0.80512.
We used data on deaths in the municipality from 2002 to 2016, recorded in the Sistema 
de Informações sobre Mortalidade (SIM – Mortality Information System)13. The data 
source was the Programa de Aprimoramento das Informações de Mortalidade (PRO-AIM 
– Mortality Information Improvement Program), municipal administrator of the SIM 
and responsible for feeding information, sending it to the federal base and maintaining 
the municipal system. PRO-AIM has methods to improve the information contained in 
death certificates, in order to achieve and maintain a good quality of the system, such 
as sending letters to certifying doctors for clarification of doubts, investigation with 
the Instituto Médico Legal and the Serviço de Verificação de Óbitos, among others14. 
To estimate the rates, we used population estimates of the Fundação Sistema Estadual 
de Análise de Dados (SEADE)11.
Death from chronic hepatitis B was defined as those with the following codes from 
the International Classification of Diseases (ICD-10)15: B16.0 [acute hepatitis B with 
Delta-agent (co-infection) with hepatic coma], B16.1 [acute hepatitis B with Delta-agent 
(co-infection) without hepatic coma], B16.2 [acute hepatitis B without Delta-agent with 
hepatic coma], B16.9 [acute hepatitis B without Delta-agent and without hepatic coma], 
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B17,0 [acute delta-super infection of hepatitis B carrier], B18.0 [chronic viral hepatitis B 
with Delta-agent] and B18.1 [chronic viral hepatitis B without Delta-agent] The definition 
of death from hepatitis C included ICD-10 codes B17.1 [acute hepatitis C] or B18.2 [chronic 
viral hepatitis C]16.
The underlying cause of death is defined by the World Health Organization as “(a) the disease 
or injury which initiated the train of morbid events leading directly to death, or (b) the 
circumstances of the accident or violence which produced the fatal injury.” Associated causes 
are all those described in the death certificate different from the underlying cause, that is, 
conditions that contributed to the death process (contributors) or that were complications of 
the underlying cause (consequential). All those described in the death certificate constitute 
multiple causes, that is, the underlying and associated causes15,16.
Initially, we only considered deaths with hepatitis B or C as underlying cause, to estimate 
the mortality rates and for trend analysis. Then, we analyzed the frequency with which 
hepatitis B or C were associated with deaths that had other underlying causes. For this, 
the associated causes for defining death were verified, that is, we considered the presence 
of the ICD-10 codes15 previously mentioned in any line of the death certificate17.
The gross mortality rate was estimated as the coefficient between total of deaths attributed 
to hepatitis B or C and the population in the studied age group residing in the municipality 
of São Paulo and multiplied by 100,000. The mortality coefficients were standardized by 
the direct method, using as reference the population of the 2010 census of the municipality 
of São Paulo.
The trend analysis was performed using a linear regression model for time series with the 
Prais-Winsten method, in order to minimize the first-order autocorrection of residues. The 
dependent variables were the standardized mortality rates from hepatitis B and C, and the 
independent variable was the calendar year18. We used the software Stata, version 15, for 
the statistical analysis of the data.
The project was approved by the Ethics Committee of the Municipal Health Secretariat of 
the city of São Paulo (Opinion No. 510.009, February 6, 2014).
RESULTS
Hepatitis B
From 2002 to 2016, 1,243 deaths were recorded in the SIM in the city of São Paulo 
mentioning viral hepatitis B, being 540 (43.44%) coded as underlying cause and 703 
(56.55%) as associated cause.
Among the 540 deaths with hepatitis B as underlying cause, 127 (23.52%) were due to acute 
infection and 413 (76.48%) due to chronic infection. Among the patients, 69.60% were male 
and 30.40% were female. The predominant race/color was white (61.11%), and the majority 
(61.65%) had less than 8 years of schooling. The mean age of females was 66.00 years, higher 
than that of males (58.61 years). About two thirds of deaths were of people under 70 years 
of age, and this percentage is higher in males, with 75.83% (Table 1). No deaths of people 
under 15 years of age were recorded.
As for the associated causes, we found 289 (53.52%) deaths with liver cirrhosis and 22 (4.07%) 
with hepatocellular carcinoma (data not shown in tables).
From 2002 to 2016, mortality rates from hepatitis B as underlying cause varied from 0.17 
(2003 and 2006) to 0.58 (2013) per 100,000 inhabitants-year. There was an annual decline 
of 5.10% (95%CI: -8.26; -1.82%) in males (-4.75%; 95%CI: -7.03; -2.42%), but not in females 
(-6.79%; 95%CI: -14.10; 1.14%) (Figure 1 and Table 2).
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Hepatitis B was mentioned in 703 deaths whose underlying cause were diseases constant 
in ICD-10 chapters. The highest proportion is associated with diseases from Chapter II, 
referring to neoplasms (C00-D48), with 42.53% of deaths (n = 299), and Chapter I, referring 
to infectious and parasitic diseases (A00-B99), with 30.44% (n = 214). Among neoplasms, liver 
cell carcinoma (C22.0) (56.18%, 169/299) and unspecified malignant liver neoplasm (C22.9) 
Table 1. Characteristics of deaths due to hepatitis B and C as underlying causes, São Paulo, SP, 2002–2016.
Variable
Hepatitis B (n = 540) Hepatitis C (n = 3,194)
n % n %
Sex
Female 164 30.40 1,433 44.90
Male 376 69.60 1,761 55.10
Age group
15–34 20 3.71 45 1.30
35–54 164 30.43 885 27.80
50–69 191 35.43 1,372 43.00
≥ 70 165 30.43 892 27.90
Race/color
White 330 61.11 2,428 76.02
Black 33 6.11 137 4.29
Brown 105 19.44 400 12.52
Yellow 29 5.37 56 1.75
Indigenous – – 1 0.03
Ignored 43 7.96 172 5.39
Schooling
None 35 6.48 169 5.29
1–3 104 19.26 652 20.41
4–7 115 21.30 741 23.20
8–11 99 18.33 657 20.57
≥ 12 59 10.93 416 13.02
Ignored 128 23.70 559 17.50
Source: SIM/PRO-AIM/CEINFO/SMSSP.
Figure 1. Standardized mortality rates for hepatitis B as underlying cause, according to sex and year of 
death, São Paulo, SP, 2002–2016.
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Male 0.67 0.79 0.73 0.64 0.94 0.62 0.86 0.64 0.7 0.61 0.58 0.28 0.55 0.44 0.41
Total 0.54 0.58 0.49 0.37 0.58 0.49 0.53 0.43 0.48 0.43 0.36 0.17 0.29 0.29 0.34
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stand out, with 57 deaths (19.06%, 57/299). Among infectious diseases, those associated with 
HIV stand out (B20.0, B20.1, B20.3, B20.6, B20.7, B20.8, B21.0, B22.7, B24), with 172 deaths 
(80.37%, 172/214). Among these, 14 deaths also stand out, in which the underlying cause 
was hepatitis C (B17.1 and B18.2) (6.54%, 14/214). In Chapter XI – Diseases of the Digestive 
System, 28 deaths due to diseases related to alcohol intake are noticeable (K70.0, K70.1, 
K70.3, K70.4 and K70.9) (data not shown in tables).
Hepatitis C
From 2002 to 2016, 6,419 deaths were recorded with mention to hepatitis C, being 3,194 
(49.76%) as underlying cause and 3,225 (50.24%) as an associated cause in residents of the 
city of São Paulo.
Among the 3,194 people who died with hepatitis C as underlying cause, 55.10% were males 
and 44.90% females. The race/color white was in 76.02% of the records, and 48,90% of the 
patients had less than 8 years of schooling. Mean age was 61.72 years, greater among women 
(65.64 years) compared with men (58.51 years). There were no records of deaths in children 
under 15 years of age. It was found that 72.12% of the deaths were of people under 70 years 
of age, being this percentage higher in males, with 81.91% (Table 1).
In addition, 1,801 deaths (56.41%) from hepatitis C also had hepatic cirrhosis as associated 
cause. Of these cases, women (44.50%) had a mean age of 66.22 years, and men (55.50%), 
57.93 years. We identified 196 (6,14%) deaths with hepatocellular carcinoma as associated 
cause (data not shown in tables).
The mortality rates from hepatitis C as underlying cause showed an increase of 5.65% 
per year (95%CI 2.99; 8.39%) between 2002 (1.99/100,000 inhabitants-year) and 2009 
(3.07/100,000 inhabitants-year), both in males (4.60%; 95%CI 2.41;6.84%) and females 
(6.90%; 95%CI 3.03;10.91%). From 2009 to 2016, there was an annual decrease trend of 
4.79% (95%CI -7.44; -2.07), decreasing to 1.98/100,000 inhabitants in 2016. This decline 
was found in males (-4.95%; 95%CI -7.63; -2.19%), but not in females (-5.29%; 95%CI -10.98; 
0.76%) (Figure 2 and Table 2).
In relation to the 3,225 deaths mentioning hepatitis C as associated cause, the greater 
proportion has neoplasms as underlying cause (Chapter II of ICD-10, C00-D48, n = 1,246, 
38.63%), followed by infectious and parasitic diseases (Chapter I of ICD-10, A00-B99, n = 893, 
27.69%). Among the neoplasms, liver cell carcinoma (C22.0) accounted for 59.95% of deaths 
(747/1,246), followed by unspecified malignant liver neoplasm (C22.9) (14.77%, 184/1,246). 
Table 2. Mean annual variation in mortality rates from hepatitis B and C as underlying causes, according 







2002–2016 General -5.10 -8.26 -1.82
Male -4.75 -7.03 -2.42
Female -6.79 -14.10 1.14
Hepatitis C
2002–2009 General 5.65 2.99 8.39
Male 4.60 2.41 6.84
Female 6.90 3.03 10.91
2009–2016 General -4.79 -7.44 -2.07
Male -4.95 -7.63 -2.19
Female -5.29 -10.98 0.76
6
Hepatitis B and C mortality in São Paulo Sato APS et al.
https://doi.org/10.11606/s1518-8787.2020054002231
Among infectious diseases, 78.61% of deaths (702/893) had diseases associated to HIV as 
underlying cause (B20.0, B20.1, B20.2, B20.3, B20.6, B20.7, B20.8, B21.0, B21.1, B21.7, B21.8, 
B22.0, B22.7, B23.2, B24), and 7.61% (68/893) had hepatitis B (B16.2, B16.9, B18.1). It is worth 
noting that 113 individuals died of liver diseases related to alcohol intake (K70.0, K70.1, 
K70.3, K70.4 and K70.9) (data not shown in tables).
DISCUSSION
The findings of this study showed a trend of declined mortality from hepatitis B and C in 
recent years in the municipality of São Paulo, particularly in males. These infections were 
important causes associated to liver cell carcinoma and HIV. In addition, the proportion 
of individuals who died under 70 years of age stands out (about 70%).
The analysis of mortality trend from hepatitis B showed reduction, particularly in men. 
In the USA, the mortality trend from hepatitis B between 1999 and 2007 showed that the 
annual age-adjusted mean was relatively constant19. But, in other places, such as Taiwan, 
a hyper-endemic region in past decades, there has been sharp decreases4,20,21. We suggest 
that the decreased mortality rates from hepatitis B in Brazil may be attributed in part to 
vaccination, with decreased prevalence, but also to prevention measures against infections 
by HIV initiated in the 1980s, as observed in other countries4,22,23.
In relation to mortality from hepatitis C, there was a mean increase trend of 5.65% per year 
between 2002 and 2009, in both sexes, and reduction of 4.79% from 2009 to 2016, in males. 
In the US, the standardized annual mortality rate increased and exceeded AIDS mortality 
between 1999 and 200719. In Brazil, the percentage drop in the second period stands out, 
which may be, in part, due to the treatment instituted in the Country at the beginning of 
the previous decade, with double therapy, used until 2014, including pegylated interferon 
as one of its components, in addition to the increased uptake of infected people by health 
services24-26. In 2015, the Ministry of Health instituted the treatment with new direct-acting 
antivirals, which show efficacy of more than 90% in curing hepatitis C and lower rates of 
adverse effects27.
Clinical care for the patient with HCV has advanced considerably, due to the evolution of 
diagnostic procedures and the improvement in therapy and prevention. The treatment of 
the infection has been proposed and improved for about 20 years, with a therapeutic arsenal 
of progressively better efficacy.
Source: SIM/PRO-AIM/CEINFO/SMSSP.
Figure 2. Standardized mortality rates for hepatitis C as underlying cause, according to sex and year of 
death, São Paulo, SP, 2002–2016.
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Male 2.42 2.65 3.05 3.11 2.99 3.31 3.36 3.39 3.24 2.80 2.72 3.42 2.24 2.46 2.40
Total 1.99 2.03 2.66 2.52 2.58 2.60 2.83 3.07 2.84 2.48 2.11 2.76 2.18 2.25 1.98
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In many countries, the incidence of hepatitis B and C has decreased due to fewer new 
infections. However, the prevalence of severe liver diseases continues to increase, since there 
is a contingent of people infected with HBV and HCV in past decades who are unaware of 
their condition or who were diagnosed late, when they show signs and symptoms of severe 
liver disease, such as cirrhosis and HCC, which contributes to premature death9,28.
In the US, a cohort study, from 2006 to 2010, showed mean age of 57 years for deaths from 
hepatitis C29. Another study conducted in the city of New York, with a casuistry from 2000 
to 2011, pointed out that 64.10% of the deaths of individuals infected by HCV occurred 
before 65 years of age30.
In this study, it was observed that at least two thirds of deaths from hepatitis B and C affected 
individuals under the age of 70, that is, those born between 1945 and 1965 (“baby boomers”). 
In the case of hepatitis C, these people became infected mainly before the incorporation of 
screening in blood banks and new technologies of products and processes related to the 
control of blood and blood products, as well as biosecurity standards in health services31. 
This finding strengthens the recommendation for Anti-HCV testing in people born in 
this period, since the infection may be asymptomatic in 75% of the cases32, as well as for 
instituting early treatment and vaccination against HBV in these carriers, according to the 
recommended protocol, preventing the aggravation of their condition33.
The significant proportion of hepatitis B and C contributing as causes associated with HCC 
and HIV is consistent in other findings in literature. A systematic review of studies published 
in several countries showed that chronic viral hepatitis due to HBV and HCV contribute 
to the majority of HCC occurences33. Globally, 78% of HCC infections were attributed to 
HBV (53%) and HCV (25%), confirming that chronic hepatitis B and C represent the main 
cause of primary liver cancer in the world7-8,33. The co-infection of viral hepatitis with HIV 
may be explained by the common routes of infection, mainly parenteral and sexual34, and 
is associated with a higher risk of death27,35. Progression from liver fibrosis to cirrhosis is 
accelerated in individuals with concomitant hepatitis C and HIV36.
Mortality data from this study may be underestimated due to the absence of hepatitis B 
and C in the death certificate, either as underlying or associated cause28. The associated 
causes of death were also studied to try to understand the effect of the under-registration 
of hepatitis B and C as underlying cause, especially when associated with liver cirrhosis, 
HCC and HIV infection37.
Mortality statistics according to underlying cause no longer show the total impact of a disease 
or aggravation in a set of deaths38. This study enabled this broader and more complete view, 
evidencing the presence of viral hepatitis B and C as associated causes, in order to contribute 
to the knowledge of the epidemiological profile of these diseases in our environment.
The data found show the importance of prevention and early diagnosis and treatment of 
hepatitis B and C. The contribution of this study is to provide a baseline for new studies on 
mortality trend and evaluation of the impact of new interventions, considering the expansion 
of diagnosis and treatment offer, including the most recent antivirals in Brazil, since 201527, 
regardless of the degree of liver fibrosis, since 201939. In addition, these results may support the 
achievement of predicted goals for eliminating hepatitis B and C in the city of São Paulo39,40.
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